Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Grant or award Director acquired 6,408 shares (grant or award)
  2. 4 Grant or award Director acquired 6,408 shares (grant or award)
  3. 4 Grant or award Director acquired 6,408 shares (grant or award)
  4. 4 Grant or award Director acquired 6,408 shares (grant or award)
  5. 4 Grant or award Director acquired 12,816 shares (grant or award)
  6. 8-K Event Shareholder vote results
  7. 8-K Event Regulation FD disclosure
  8. SCHEDULE 13G Stake Statement of Beneficial Ownership
  9. 10-Q Report Quarterly Report
  10. 8-K Event Results of operations
  11. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  12. 3/A Insider 3/A
  13. DEFA14A Proxy Proxy Materials
  14. ARS Other Annual Report to Security Holders
  15. DEF 14A Proxy Proxy Statement
  16. 3 Insider Initial Statement of Ownership
  17. 8-K Event Agreement ended
  18. 8-K Event New debt or obligation · Regulation FD disclosure
  19. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  20. 8-K Event Regulation FD disclosure

Page 2 of 40 · 789 filings